The Conversation (0)
VIVO Cannabis entered an agreement with Pharmascience to develop novel cannabis products for medical use.
VIVO Cannabis (TSXV:VIVO) entered an agreement with Pharmascience to develop novel cannabis products for medical use.
As quoted in the press release:
On behalf of VIVO, Pharmascience is creating a line of specific medical cannabis formulations that are intended to maximize therapeutic benefit to patients by using pharmaceutical quality standards. It is anticipated that health care professionals and patients will welcome the availability of precisely-controlled, high-quality, standardized dosage forms of cannabis.
“VIVO, through our Beacon Medical division, is committed to launching innovative precise-dosage formats for medical cannabis, with the intent of enhancing patient safety and efficacy. We are pleased to combine our strengths with those of Pharmascience for the benefit of our current and future medical patients,” commented Barry Fishman, CEO of VIVO.
“We are very excited to associate with VIVO, a recognized Canadian Licensed Producer with a strong focus on quality and innovation, to develop new formulations that will benefit medical cannabis patients in Canada and in international markets where the use of cannabis-containing products for medical use is permitted,” added David Goodman, CEO of Pharmascience.
Click here to read the full press release.
Source: globenewswire.com
